You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Imatinib Mesylate (Gleevec™) for the Treatment of Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours

Version: 3 ID: 11-7 mai 2015
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
S. Verma, J. Younus, D. Stys-Norman, A.E. Haynes, M. Blackstein , Sarcoma Disease Site Group

Patient Population

Adult patients with unresectable or metastatic GIST expressing KIT (CD117+).

Research Question(s)

Does treatment with imatinib mesylate (Gleevec™) have palliative benefit, in terms of tumour response, disease progression, survival or quality of life, for patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT tyrosine kinase receptor (identified by CD117 immunohistochemical staining)?

pdf download Full Report (PDF) (663.14 Ko)